Buccal tablet with throat clearing and nourishing functions as well as preparation method and application of buccal tablet
By developing an oral lozenge containing licorice extract and isolivolin, the problems of laryngeal microbial disorders and drug side effects in the treatment of chronic pharyngitis were solved, and the treatment effects of clearing heat and detoxifying, throat protection and no side effects were achieved, which significantly improved Symptoms of chronic pharyngitis and pharyngeal inflammation.
Patent Information
- Application Number
- CN202411036258.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art can easily lead to normal bacterial dysplasia in the treatment of chronic pharyngitis, leading to double infection and poor treatment effect. The overall concept of traditional Chinese medicine is different from the single treatment of Western medicine, and there is a lack of effective medicinal and food homologous species. Chinese herbal medicine preparation.
Develop a throat-clearing oral lozenges containing sorbitol, citric acid, licorice extract, isoglycerin, mint, edible flavors, food coloring and flavoring agents, made by specific preparation methods, providing a A Chinese herbal preparation with the same origin as medicine and food, used to treat throat discomfort.
This oral lozenge has the effects of clearing heat and detoxifying, protecting the throat, and has no side effects. It can effectively improve the symptoms of chronic pharyngitis, reduce the number of white blood cells and lymphocytes, improve inflammation of the pharyngeal tissue, and significantly improve the therapeutic effect.
Smart Images

Figure CN118947800A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of buccal tablets, and in particular to a buccal tablet with the function of clearing the throat and moistening the throat, and a preparation method and application thereof. Background Art
[0002] In the era of great health, people have higher and higher requirements for food, and functional products are considered to be the future development direction of high-end food. Due to irregular diet, lack of exercise, smoking, drinking and other unhealthy lifestyles, as well as excessive mental stress from work and life, environmental pollution and other factors, people's bodies are in a sub-healthy state. When people are in a sub-healthy state for a long time, they are bound to increase the risk of pharyngitis, visual fatigue or cardiovascular and cerebrovascular diseases.
[0003] Throat discomfort mainly refers to a series of uncomfortable symptoms caused by chronic pharyngitis and inflammatory reactions in the throat. Chronic pharyngitis is a typical symptom, which manifests as diffuse inflammation of the pharyngeal mucosa, submucosal and lymphatic tissues. Western medicine often uses antibiotics or dexamethasone, compound borax solution, furazolidone mouthwash, etc. to treat chronic pharyngitis; however, the abuse of antibiotics can cause the normal flora of the throat to be imbalanced, which in turn causes secondary infection, poor treatment effect, and easy recurrence. Traditional Chinese medicine treatment focuses on the overall concept, with a definite effect, small toxic and side effects, and a mild and lasting effect; in view of this, in recent years, researchers have paid more attention to the treatment of this disease with traditional Chinese medicine. Traditional Chinese medicine believes that the throat is the key point for the circulation and convergence of the twelve meridians, and is connected to the five internal organs through the meridians. Therefore, dysfunction of the internal organs often disturbs the meridians, affects the throat, and causes various diseases. Most doctors believe that lung and kidney yin deficiency and virtual fire are the basic etiology and pathogenesis of chronic pharyngitis. Lung yin deficiency means that body fluid cannot be transported upward, virtual heat burns the throat; kidney yin deficiency and insufficient body fluid will cause the throat to lose nourishment, virtual fire will follow the meridians and accumulate in the throat, or be invaded by wind and heat evil, causing heat stagnation in the lungs and stomach, and heat steaming upward, stagnation in the throat and causing illness. Traditional Chinese medicine uses plant-derived drugs, and most of them are leaves, flowers, and fruits that are both medicinal and edible. They are highly recognized and have few adverse reactions, making them suitable for long-term consumption.
[0004] Licorice belongs to the leguminous plant family and was first recorded in the Shennong's Herbal Classic. The medicinal parts are the dried roots and rhizomes, which have the effects of clearing away heat and detoxifying, tonifying the spleen and replenishing qi, moistening the lungs and resolving phlegm, relieving pain, and harmonizing various medicines. Modern research shows that the chemical components of licorice include flavonoids, saponins, alkaloids, etc., which have multiple pharmacological effects such as anti-inflammatory, antioxidant, and immunomodulatory. Therefore, it is very important to give full play to the effects of licorice and develop a new type of Chinese herbal medicine preparation that can effectively treat throat discomfort. Summary of the invention
[0005] The invention provides a lozenge with the function of clearing and moistening the throat, which is used to provide a Chinese herbal medicine preparation of the same origin as medicine and food for treating throat discomfort.
[0006] The first aspect of the present invention provides a lozenge with the function of clearing the throat and moistening the throat. The raw materials required for preparing the lozenge include: 0.2-1 part of sorbitol, 0.02-0.2 part of citric acid, 0.05-1 part of licorice extract, 0.002-0.01 part of isoliquiritigenin, 0.01-0.1 part of mint, 0.002-0.02 part of edible flavor, 0.002-0.02 part of edible coloring, and 0-0.1 part of flavoring agent;
[0007] Based on each of the buccal tablets, the content of isoliquiritigenin is 3 to 12 mg.
[0008] In the present invention, in the raw materials required for preparing the buccal tablet, the proportion of sorbitol can be, for example, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part or a range consisting of any two thereof; the proportion of citric acid can be, for example, 0.02 part, 0.03 part, 0.04 part, 0.05 part, 0.06 part, 0.07 part, 0.08 part, 0.09 part, 0.10 part, 0.11 part, 0.12 part, 0.13 part, 0.14 part, 0.15 part, 0.16 part, 0.17 part, 0.18 part, 0.19 part, 0.20 part, 0.21 part, 0.22 part, 0.23 part, 0.24 part, 0.25 part, 0.26 part, 0.27 part, 0.28 part, 0.29 part, 0.30 part, 0.31 part, 0.32 part, 0.33 part, 0.34 part, 0.35 part, 0.36 part, 0.37 part, 0.38 part, 0.39 part, 0.40 part, 0.41 part, 0.42 part, 0.43 part 2 parts or the range consisting of any two thereof; the number of parts of licorice extract can be, for example, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part or the range consisting of any two thereof; the number of parts of isoliquiritigenin can be, for example, 0.002 parts, 0.003 parts, 0.004 parts, 0.005 parts, 0.006 parts, 0.007 parts, 0.008 parts, 0.009 parts, 0.01 parts or the range consisting of any two thereof; thin The amount of the edible flavor can be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, or any two thereof; the amount of the edible flavor can be, for example, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, the number of portions of edible coloring can be, for example, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, or a range consisting of any two of them; the number of portions of flavoring can be, for example, 0, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, or a range consisting of any two of them.
[0009] Based on each of the buccal tablets, the content of isoliquiritigenin may be in the range of 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg or any two thereof.
[0010] In the present invention, the licorice extract may be a commercially available product, wherein the isoliquiritigenin content is not less than 0.30%.
[0011] In the present invention, the mint is mint leaf powder.
[0012] In the present invention, the food coloring is green food coloring or brown food coloring.
[0013] In the present invention, the flavoring agent is selected from at least one of roxburghii powder, blueberry powder, grapefruit powder and orange powder; the preparation method of the flavoring agent can be carried out according to conventional technical means in the art.
[0014] In the present invention, the mass of each of the buccal tablets is 0.7 to 1 g, for example, 0.7 g, 0.8 g, 0.9 g, 1.0 g or any combination thereof.
[0015] In the present invention, the buccal tablet is prepared by a preparation method comprising the following steps:
[0016] Step 1, adding the sorbitol into a batching pot, raising the temperature until the sorbitol is dissolved into a liquid state; adding citric acid at 150-200° C., boiling for 5-10 minutes; adding the licorice extract after cooling to 120° C.; adding the isoliquiritigenin, mint, edible flavor, edible coloring and flavoring after cooling to 70-90° C., and mixing well to obtain a mixed slurry;
[0017] Step 2: pour the mixed slurry into a mold, and after cooling and forming, demould to obtain the buccal tablet.
[0018] The second aspect of the present invention provides a method for preparing the above-mentioned buccal tablet, comprising:
[0019] Step 1, adding the sorbitol into a batching pot, raising the temperature until the sorbitol is dissolved into a liquid state; adding citric acid at 150-200° C., boiling for 5-10 minutes; adding the licorice extract after cooling to 120° C.; adding the isoliquiritigenin, mint, edible flavor, edible coloring and flavoring after cooling to 70-90° C., and mixing well to obtain a mixed slurry;
[0020] Step 2: pour the mixed slurry into a mold, and after cooling and forming, demould to obtain the buccal tablet.
[0021] Furthermore, in step 2, the cooling temperature is 15-35°C.
[0022] The third aspect of the present invention provides the use of the above-mentioned buccal tablet in preparing a product for treating pharyngitis.
[0023] Furthermore, the buccal tablets can be taken orally, with 9 tablets taken per day.
[0024] The buccal tablet provided by the invention has a simple and convenient preparation process, has the effects of clearing away heat and detoxifying, protecting the throat, and has no side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The effect of licorice extract on xylene-induced ear swelling, where * indicates p < 0.05 compared with the model group, and ** indicates p < 0.01 compared with the model group;
[0026] Figure 2 The effect of licorice extract on the toe swelling of mice induced by 1% carrageenan, where * indicates p < 0.05 compared with the model group, and ** indicates p < 0.01 compared with the model group;
[0027] Figure 3a This is the total ion chromatogram of licorice extract in positive ion mode;
[0028] Figure 3b This is the total ion current of licorice extract in negative ion mode;
[0029] Figure 4 is the total ion current of rat serum after taking licorice extract; wherein A is the total ion current of blank serum in positive ion mode; B is the total ion current of blank serum in negative ion mode; C is the total ion current of drug-containing serum in positive ion mode; D is the total ion current of drug-containing serum in negative ion mode;
[0030] Figure 5 It is a chromatogram comparison diagram of the licorice extract test solution and the isoliquiritigenin reference solution; wherein A is the chromatogram of the isoliquiritigenin reference solution, and B is the chromatogram of the licorice extract test solution;
[0031] Figure 6 The effects of the buccal tablets and isoliquiritigenin provided in Example 3 on the white blood cells (WBC), lymphocytes (LYM) and monocytes (MONO) in the serum of rats with acute pharyngitis caused by ammonia; wherein A is the effect on white blood cells (WBC), B is the effect on lymphocytes (LYM), and C is the effect on monocytes (MONO); ## indicates p<0.01 compared with the blank group, and ** indicates p<0.01 compared with the model group;
[0032] Figure 7 The effects of the buccal tablets and isoliquiritigenin provided in Example 3 on the pathological changes of pharyngeal tissue in rats with acute pharyngitis (HE, × 400); wherein A is the pharyngeal tissue image of rats in the blank group, B is the pharyngeal tissue image of rats in the model group, C is the pharyngeal tissue image of rats in the licorice extract buccal tablet group, D is the pharyngeal tissue image of rats in the low-dose isoliquiritigenin group, E is the pharyngeal tissue image of rats in the medium-dose isoliquiritigenin group, F is the pharyngeal tissue image of rats in the high-dose isoliquiritigenin group, and G is the pharyngeal tissue image of rats in the positive drug group. DETAILED DESCRIPTION
[0033] In order to make the purpose, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] The licorice extract (licorice extract powder) used in the following examples was provided by Xinjiang Alaer Xinnong Licorice Industry Co., Ltd.
[0035] Example 1
[0036] The raw materials required for preparing the buccal tablet provided in this embodiment include 600g sorbitol, 140g citric acid, 300g licorice extract, 4g isoliquiritigenin, 60g mint leaf powder, 10g edible flavor, and 2g edible coloring.
[0037] The preparation method comprises:
[0038] Step 1. Add 600g of sorbitol to the ingredient pot, open the steam valve to heat it to make it completely dissolved, and continue to heat it to 180°C, then add 140g of citric acid, and boil it for 5 minutes while stirring; when it cools to 120°C, add 300g of licorice extract, stirring continuously, and when the temperature continues to cool to 80°C, add 4g of isoliquiritigenin, 60g of mint leaf powder, 2g of food coloring, and 10g of edible flavoring, stirring continuously to mix evenly to obtain a mixed slurry.
[0039] Step 2, adding the mixed slurry prepared in step 1 to a pouring machine, pouring at 0.8 g / piece, after pouring, rapidly cooling the entire model plate to form the candy, cooling the temperature to 20°C, dropping the candy from the module, removing the unqualified candy, and packaging the qualified products into bags, to obtain 1100 qualified buccal tablets in total. The buccal tablet has a yellow-brown oval appearance, is shiny, has a hard texture, has a strong cool feeling, licorice fragrance and lubrication when entering the mouth, and is refreshing and refreshing.
[0040] Example 2
[0041] The raw materials required for preparing the lozenges provided in this embodiment include 200g of sorbitol, 100g of citric acid, 1000g of licorice extract, 3g of isoliquiritigenin, 100g of mint leaf powder, 4g of edible flavor, 20g of edible coloring and 100g of blueberry powder.
[0042] The preparation method comprises:
[0043] Step 1. Add 200g of sorbitol to the ingredient pot, open the steam valve to heat it to make it completely dissolved, and continue to heat it to 180°C, then add 100g of citric acid, and boil it for 5 minutes while stirring; when it cools to 120°C, add 1000g of licorice extract and keep stirring. When the temperature continues to cool to 80°C, add 3g of isoliquiritigenin, 100g of mint leaf powder, 4g of edible flavor, 20g of food coloring, and 100g of blueberry powder, and keep stirring to mix evenly to obtain a mixed slurry.
[0044] Step 2, add the prepared mixed slurry into the pouring machine, pour at 0.8g / piece, and obtain 1700 qualified throat-clearing and throat-soothing buccal tablets. The licorice extract buccal tablets are light purple oval in appearance, shiny, hard in texture, and have a strong cool feeling, blueberry fragrance, licorice fragrance and lubrication, refreshing and refreshing. Blueberries not only contain extremely high conventional nutrients, but are also rich in anthocyanins, which have the effects of protecting eyes, improving memory, slowing down aging, lowering blood sugar, lowering cholesterol, and protecting heart and blood vessels. Moreover, blueberries have a moderate sweet and sour taste and a blueberry fruit flavor.
[0045] Example 3
[0046] The raw materials required for preparing the buccal tablet provided in this embodiment include 600g sorbitol, 60g citric acid, 80g licorice extract, 4g isoliquiritigenin, 40g mint leaf powder, 2g edible flavor, 10g edible coloring and 100g roxburghii powder.
[0047] The preparation method comprises:
[0048] Step 1. Add 600g of liquid sorbitol to the ingredient pot, open the steam valve and heat to make it completely dissolved, and continue to heat to 180°C, then add 60g of citric acid, and boil for 5 minutes while stirring; when cooled to 120°C, add 80g of licorice extract, stirring continuously, and when the temperature continues to cool to 80°C, add 4g of isoliquiritigenin, 40g of mint leaf powder, 2g of edible flavor, 10g of food coloring, and 100g of sea buckthorn powder, stirring continuously to mix evenly to obtain a mixed slurry.
[0049] Step 2, add the prepared mixed slurry to the pouring machine, pour according to 0.8g / , obtain 1000 pieces of qualified licorice extract buccal tablet products, the licorice extract buccal tablet appearance is light purple oval, glossy, hard texture, entrance has stronger cooling feeling, roxburghii fruit sour taste and licorice herb fragrance and lubrication, refreshing and fresh. Roxburghii also has high medicinal value and food therapy value, is rich in rich tannin, vitamin B, vitamin C, has the effects such as digestion, astringency and antidiarrhea, quench thirst and relieve summer heat. Cure mainly the diseases such as abdominal distension caused by food accumulation, dysentery, diarrhea, spontaneous sweating and night sweating, hemorrhoidal bleeding, enteritis, thirst, dry mouth, dry throat. And roxburghii itself has sour and sweet taste, and more licorice buccal tablets have added a kind of sour and sweet flavor.
[0050] Experimental Example 1: Effect of Licorice Extract on Xylene-Induced Ear Swelling in Mice
[0051] Male KM mice that passed the quarantine were selected and randomly divided into 4 groups according to body weight, namely, low-dose licorice extract group (0.3g / kg / d), high-dose licorice extract group (1g / kg / d), and positive drug (indomethacin enteric-coated tablets) group (5mg / kg), 10 mice in each group, and gavage was given once a day for 7 consecutive days. The mice in the model group had a normal diet and were given an equal volume of normal saline. 60 minutes after the last administration, 20μL of 100% xylene was evenly applied to the front and back of the right ear, and the left ear was used as a control. After 90 minutes, the mice were killed by dislocating the neck, and the left and right ears were cut along the auricle baseline, and round ear pieces were punched at the same position on the left and right with an 8mm diameter puncher, respectively, and weighed on an analytical balance. The difference in weight between the left and right ears was used as the swelling degree for statistical testing.
[0052] Swelling degree (g) = weight of left ear piece (g) - weight of right ear piece (g)
[0053] The results are as follows Figure 1 As shown, compared with the model group, high-dose licorice extract has a significant inhibitory effect on mouse ear swelling (p<0.05). The experimental results show that high-dose licorice extract can significantly reduce the swelling rate of mouse ears and has a certain effect on resisting acute exudative inflammation.
[0054] Experimental Example 2 Effect of Licorice Extract on 1% Carrageenan-induced Mouse Toe Swelling
[0055] Male KM mice that passed the quarantine were selected and randomly divided into 4 groups according to body weight, namely, low-dose licorice extract group (0.3g / kg / d), high-dose licorice extract group (1g / kg / d), and positive drug (indomethacin enteric-coated tablets) group (5mg / kg), 10 mice in each group, and intragastric administration was performed once a day for 7 consecutive days. The mice in the model group had a normal diet and were given an equal volume of normal saline. 60 minutes after the last administration, 50μL 1% carrageenan was subcutaneously injected into the left hind toe of each mouse, and then the thickness of the toe was measured 1, 2, 4, and 6 hours after inflammation, and the toe swelling rate was calculated.
[0056] Swelling degree (mm) = left toe thickness (mm) - right toe thickness (mm)
[0057] The results are as follows Figure 2 As shown, compared with the model group, low and high doses of licorice extract can significantly reduce the swelling rate of mouse toes, have a certain effect on anti-acute exudative inflammation, and show a certain dose dependence.
[0058] Experimental Example 3 Characterization of chemical components of licorice extract in vivo and in vitro and quality control analysis of isoliquiritigenin
[0059] 3.1 Characterization of chemical components of licorice extract
[0060] Take an appropriate amount of licorice extract, crush it through a No. 5 sieve, accurately weigh 2 g, sonicate it in 25 mL of methanol for 30 minutes, filter it, and pass the filtrate through a 0.22 μm microporous filter membrane to obtain a licorice extract test solution;
[0061] Preparation of reference solution: Accurately weigh 1 mg of isoliquiritigenin and glycyrrhetinic acid, add methanol to ultrasonically dissolve, make up to volume, and filter through a 0.22 μm microporous membrane to prepare the mixed standard solution.
[0062] Chromatographic conditions: Hypersil GOLD C18 (100 mm × 2.1 mm, 1.9 μm); mobile phase: methanol (A)-0.15% formic acid aqueous solution (B); elution gradient: 0-1 min (95-95% B), 1-10 min (95-50% B), 10-15 min (50-20% B), 15-20 min (20-5% B), 20-23 min (5-5% B), 23-23.1 min (5-95% B), 23.1-26 min (95-95% B); flow rate: 0.2 mL / min; column temperature: 35 ° C; injection volume: 2 μL; mass spectrometry conditions: ion source is electrospray ionization source (ESI), carrier gas is nitrogen, positive and negative ion mode Full MS / dd-MS2 scanning, sheath gas flow rate 35arb, auxiliary gas flow rate 10arb, capillary voltage 3.5, 3.0kV in positive and negative ion mode, collision energy 20, 30, 50, 70, ddMS2 resolution 15000, Full Scan resolution 6000, ion transfer tube 350℃, vaporization temperature 300℃, scanning range m / z 100~1000. The total ion chromatogram of licorice extract UPLC-MS / MS is shown in Figure 3a-3b As shown, a total of compounds as shown in Table 1 can be identified and analyzed, mainly including flavonoids and terpenes.
[0063] Table 1 In vitro composition information of licorice extract
[0064]
[0065]
[0066]
[0067]
[0068] 3.2 Characterization of serum chemical components of licorice extract
[0069] Male SD mice that passed the quarantine were selected and randomly divided into two groups according to their weight, namely the blank group and the licorice extract group (0.72g / kg / d), with 7 mice in each group, and the drug was administered once a day by gavage for 7 consecutive days. The rats in the blank group had a normal diet and were given an equal volume of normal saline. They were fasted for 12 hours before sampling, but they were not allowed to drink water. 60 minutes after the last administration, they were anesthetized with 20% urethane solution, blood was collected from the abdominal aorta, left at room temperature for 1h, centrifuged at 4℃ for 10min, and the speed was 3000r / min. The upper serum was taken, mixed with the serum of the administration group, and stored at -80℃ for later use.
[0070] Preparation of blank serum solution: Accurately pipette 300 μL of rat blank serum sample into a 1.5 mL centrifuge tube, add 4 times the amount of methanol, vortex for 6 min, centrifuge at 4°C and 12000 r / min for 15 min, take the supernatant, blow dry in a centrifugal concentrator, add 100 μL of 50% methanol aqueous solution to the residue, vortex for 6 min, centrifuge at 12000 r / min for 15 min, separate the upper solution as the blank serum solution.
[0071] Preparation of drug-containing serum solution: accurately pipette 300 μL of rat drug-containing serum sample into a 1.5 mL centrifuge tube, add 4 times the amount of methanol, vortex for 6 min, centrifuge at 4°C and 12000 r / min for 15 min, take the supernatant, blow dry in a centrifugal concentrator, add 100 μL of 50% methanol aqueous solution to the residue, vortex for 6 min, centrifuge at 12000 r / min for 15 min, and separate the upper solution as the drug-containing serum solution;
[0072] Preparation of reference solution: Accurately weigh 1 mg of isoliquiritigenin and glycyrrhetinic acid, add methanol to ultrasonically dissolve, make up to volume, and filter through a 0.22 μm microporous membrane to prepare the mixed standard solution.
[0073] Chromatographic conditions: Hypersil GOLD C18 (100 mm × 2.1 mm, 1.9 μm); mobile phase: methanol (A)-0.15% formic acid aqueous solution (B); elution gradient: 0-1 min (95-95% B), 1-10 min (95-50% B), 10-15 min (50-20% B), 15-20 min (20-5% B), 20-23 min (5-5% B), 23-23.1 min (5-95% B), 23.1-26 min (95-95% B); flow rate: 0.2 mL / min; column temperature: 35 ° C; injection volume: 2 μL; mass spectrometry conditions: ion source is electrospray ionization source (ESI), carrier gas is nitrogen, positive and negative ion mode Full MS / dd-MS2 scanning, sheath gas flow rate 35arb, auxiliary gas flow rate 10arb, capillary voltage in positive and negative ion mode was 3.5 and 3.0kV, collision energy 20, 30, 50, 70, ddMS2 resolution 15000, Full Scan resolution 6000, ion transfer tube 350℃, vaporization temperature 300℃, scanning range m / z 100-1000.
[0074] like Figure 4 As shown in the figure, 17 compounds including isoliquiritigenin, glycyrrhetinic acid, chlorogenic acid, etc. were identified and analyzed in the serum of licorice extract, mainly including flavonoids and terpenes, see Table 2.
[0075] Table 2 Serum composition information of licorice extract
[0076]
[0077] 3.3 Quality Control Analysis of Isoliquiritigenin in Licorice Extract
[0078] Preparation of test solution: Take an appropriate amount of licorice extract, crush it through a No. 5 sieve, accurately weigh 1 g, ultrasonicate it in 25 mL of methanol for 30 minutes, filter it, and pass the filtrate through a 0.22 μm microporous filter membrane to obtain the licorice extract test solution.
[0079] Preparation of reference solution: Accurately weigh 1 mg of isoliquiritigenin, add methanol to dissolve by ultrasonication, make up to volume, and filter through a 0.22 μm microporous membrane to obtain a standard solution.
[0080] Chromatographic conditions: Chromatographic column: Hypersil BDS C18 (4.6mm×250mm, 5μm); Mobile phase: acetonitrile (A)-0.15% formic acid aqueous solution (B) elution gradient: 0-10min (90-51% B), 10-16min (51-45% B), 16-22min (45-10% B), 22-26min (10-90% B), 26-30min (90% B); Detection wavelength: 254nm; Flow rate: 1mL / min; Column temperature: 25℃; Injection volume: 5μL; Isoliquiritigenin retention time: 13.51min. Figure 5 As shown, the average content of isoliquiritigenin in licorice extract is 3.2794 mg / g.
[0081] Experimental Example 4 Effects of the buccal tablets and isoliquiritigenin provided in Example 3 on acute pharyngitis caused by ammonia
[0082] Isoliquiritigenin is widely used as a natural food additive with low toxicity. Therefore, isoliquiritigenin is used as a quality control indicator for licorice extract to measure the stability of the licorice extract content in licorice extract buccal tablets, and to further clarify the effect of isoliquiritigenin in treating acute pharyngitis and the amount of isoliquiritigenin added to licorice extract buccal tablets.
[0083] Male SD rats that passed the quarantine were selected and randomly divided into 7 groups according to their weight, namely, blank group, model group, licorice extract oral tablet group, isoliquiritigenin low-dose group, isoliquiritigenin medium-dose group, isoliquiritigenin high-dose group, and positive drug group, with 6 rats in each group. 15% ammonia water was sprayed into the pharynx of rats except the blank group using a laryngeal sprayer, and sprayed once at 10:00 and 16:00 every day, 3 presses / time, and stimulated continuously for 3 days to make acute pharyngitis rat models, and the blank group rats were sprayed with an equal amount of normal saline. On the 4th day, the rats in the licorice extract oral tablet group (0.72 g / kg / d), isoliquiritigenin low-dose group (3 mg / kg / d), isoliquiritigenin medium-dose group (10 mg / kg / d), and isoliquiritigenin high-dose group (30 mg / kg / d) were gavaged with corresponding concentration solutions, and the rats in the positive drug group were gavaged with aspirin solution (20 mg / kg / d) for 5 consecutive days. The rats in the blank group and the model group were fed a normal diet and given an equal volume of normal saline.
[0084] The test results are shown in Figure 6 and Figure 7 The results showed that compared with the blank group, the number of WBC, LYM and MONO in the whole blood of the model group rats increased significantly; compared with the model group, the number of white blood cells, lymphocytes and monocytes in the positive drug control group, licorice extract oral tablet group, low, medium and high doses of isoliquiritigenin rats were significantly reduced (p<0.01). The experimental results showed that the licorice extract oral tablet group and low, medium and high doses of isoliquiritigenin had a significant effect on improving the body's inflammatory state, and the inhibitory effect on monocytes was dose-dependent. No toxic side effects of the licorice extract oral tablet group and isoliquiritigenin on rat organs were observed.
[0085] The results of rat pharyngeal pathological tissue sections showed that the pharyngeal tissue structure of the blank group rats was clear, the basal fibers were arranged regularly, the mucosal epithelium was smooth and flat, and there was no inflammatory infiltration in the lower layer; the smoothness of the pharyngeal tissue mucosa of the model group rats was damaged, the upper outer layer was severely keratinized, and a large number of inflammatory cells infiltrated; the licorice extract oral tablet group and low, medium and high doses of isoliquiritigenin can significantly improve the pharyngeal tissue mucosa, epithelial keratinization, and inflammatory infiltration of rats with acute pharyngitis. The above results show that licorice extract oral tablets and isoliquiritigenin can significantly restore the damaged pharyngeal tissue of rats with acute pharyngitis induced by ammonia, and further improve the inflammatory state of the body.
[0086] The experimental analysis shows that after the treatment with licorice extract buccal tablets and isoliquiritigenin, the physical signs of rats with acute pharyngitis are significantly improved compared with the model group, the number of leukocytes, lymphocytes and monocytes are reduced to varying degrees, and the inflammatory infiltration of pharyngeal tissue in pathological sections is reduced. The above results show that the licorice extract buccal tablet group and isoliquiritigenin have a good therapeutic effect on rats with acute pharyngitis and no toxic side effects are detected. In addition, the low-dose group of isoliquiritigenin is 3mg / kg / d, which is converted to a human dosage of 3 / 6.3*60=28.5mg / d. When 9 pieces of licorice extract buccal tablets are taken orally every day, the content of isoliquiritigenin in each buccal tablet is 3.2mg / tablet. Considering the loss of 10% and the upper limit of each tablet, when the content of isoliquiritigenin in the buccal tablet is in the range of 3mg / tablet-12mg / tablet, it has a significant therapeutic effect on acute pharyngitis.
[0087] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A lozenge with the function of clearing the throat and moistening the throat, characterized in that: The raw materials required for preparing the buccal tablets include: 0.2-1 part of sorbitol, 0.02-0.2 part of citric acid, 0.05-1 part of licorice extract, 0.002-0.01 part of isoliquiritigenin, 0.01-0.1 part of mint, 0.002-0.02 part of edible flavor, 0.002-0.02 part of edible coloring, and 0-0.1 part of flavoring agent; Based on each of the buccal tablets, the content of isoliquiritigenin is 3 to 12 mg.
2. The buccal tablet according to claim 1, characterized in that The content of isoliquiritigenin in the liquorice extract is not less than 0.30%.
3. The buccal tablet according to claim 1, characterized in that The mint is mint leaf powder.
4. The buccal tablet according to claim 1, characterized in that The food coloring is green food coloring or brown food coloring.
5. The buccal tablet according to claim 1, characterized in that The flavoring agent is selected from at least one of roxburghii powder, blueberry powder, grapefruit powder and orange powder.
6. The buccal tablet according to claim 1, characterized in that The mass of each lozenge is 0.7 to 1 g.
7. The buccal tablet according to any one of claims 1 to 6, characterized in that: The buccal tablet is prepared by a preparation method comprising the following steps: Step 1, adding the sorbitol into a batching pot, raising the temperature until the sorbitol is dissolved into a liquid state; adding citric acid at 150-200° C., boiling for 5-10 minutes; adding the licorice extract after cooling to 120° C.; adding the isoliquiritigenin, mint, edible flavor, edible coloring and flavoring after cooling to 70-90° C., and mixing well to obtain a mixed slurry; Step 2: pour the mixed slurry into a mold, and after cooling and forming, demould to obtain the buccal tablet.
8. The method for preparing the buccal tablet according to any one of claims 1 to 7, characterized in that: include: Step 1, adding the sorbitol into a batching pot, raising the temperature until the sorbitol is dissolved into a liquid state; adding citric acid at 150-200° C., boiling for 5-10 minutes; adding the licorice extract after cooling to 120° C.; adding the isoliquiritigenin, mint, edible flavor, edible coloring and flavoring after cooling to 70-90° C., and mixing well to obtain a mixed slurry; Step 2: pour the mixed slurry into a mold, and after cooling and forming, demould to obtain the buccal tablet.
9. The buccal tablet according to claim 8, characterized in that In step 2, the cooling molding temperature is 15-35°C.
10. Use of the buccal tablet according to any one of claims 1 to 7 in preparing a product for treating pharyngitis.
